Abcam, ab263223, Human GPATCH4 knockout HEK-293T cell lysate

Size: 1Kit
GPATCH4 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 3 and 2 bp deletion in exon 3.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 3 and 2 bp deletion in exon 3

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-GPATCH4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The GPATCH4 protein also known as G patch domain-containing protein 4 is a member of the G-patch domain family and has a molecular mass of approximately 102 kDa. GPATCH4 plays a mechanical role in pre-mRNA splicing where it associates with RNA and other splicing factors. This protein is expressed in various tissues with particular high levels in testis and heart. Its exact localization and interaction partners within the cell are subject to ongoing research but the consensus finds GPATCH4 interacting directly with the RNA molecule.
Biological function summary
The GPATCH4 protein contributes to the regulation of RNA processing. It functions as a part of a larger ribonucleoprotein complex involved in the assembly and functionality of spliceosomes. The integration of GPATCH4 into this complex aids in the accurate and efficient splicing of pre-mRNA an essential process for gene expression regulation. Proper functioning of GPATCH4 ensures that diverse cellular processes requiring specific mRNA molecules proceed without error.
Pathways
GPATCH4 plays important roles in the pre-mRNA splicing pathway a critical component of gene expression. This pathway necessitates the involvement of several other proteins including SF3B1 and U2AF2 which work alongside GPATCH4 in the spliceosome assembly. GPATCH4 contributes to these complex interactions facilitating the precise removal of introns from pre-mRNA strands in both major and minor splicing pathways. This activity impacts how cells respond to different physiological conditions and external stimuli.
Abnormal functioning of GPATCH4 relates to cancer and certain cardiovascular conditions making it an interesting target for medical research. Studies suggest that misregulation of the splicing process in which GPATCH4 is involved can trigger oncogenesis potentially by affecting genes that control cell proliferation. In cardiovascular diseases changes in splicing profiles sometimes involving GPATCH4 lead to maladaptive cellular responses. Research into how GPATCH4 interacts with other proteins like SF3B1 can provide insights into these disorders’ underlying mechanics offering potential avenues for therapeutic intervention.